Antifibrotic

Questions discussed in this category

When do you begin antifibrotic therapy for a patient with newly diagnosed ILD that is not IPF?

Do you base the decision on FEV1, 6MWD or symptoms at initial evaluation, or progression over time?

4 Answers available

Would you consider the use of dual antifibrotic therapy (nintedanib and pirfenidone together) for progressive fibrosing ILD?

3 Answers available

Is there a role for antifibrotic therapy in post COVID-19 pulmonary fibrosis?

1 Answer available

Papers discussed in this category

Eur Respir Rev, 2021 Dec 15

Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection.

Ann Am Thorac Soc,

Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment.

Am J Respir Crit Care Med,

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.

The European respiratory journal, 2018-08

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.

N Engl J Med, 2019 Sep 29

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Arthritis & rheumatology (Hoboken, N.J.), 2017-03

Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.

N. Engl. J. Med., 2019 May 20

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Related Topics